Certified by Founder
Lodge
LoQus23 Therapeutics Ltd
start up
United Kingdom
- Cambridge, Cambridgeshire
- 02/10/2024
- Series A
- $46,550,175
LoQus23 are discovering oral small molecule therapies targeting aberrant DNA mismatch repair to effectively treat Huntington’s and other triplet repeat diseases.
- Industry Biotechnology Research
- Website https://loqus23.com/
- LinkedIn https://www.linkedin.com/company/loqus23-therapeutics-ltd/
Feltsense | $5,100,000 | (Feb 5, 2026)
Stratus Medical | $10,000,000 | (Feb 5, 2026)
beHuman Corp. | $4,000,000 | (Feb 5, 2026)
Boomband | $4,000,000 | (Feb 5, 2026)
Bedrock Robotics | $270,000,000 | (Feb 5, 2026)
Fibr AI | $7,500,000 | (Feb 5, 2026)
Expert Intelligence™ | $4,700,000 | (Feb 5, 2026)
Positron AI | $230,000,000 | (Feb 5, 2026)
Chamber(US) | $60,000,000 | (Feb 5, 2026)
SENAI | $6,200,000 | (Feb 5, 2026)
OneDome | $25,000,000 | (Feb 4, 2026)
Naoma AI | $440,000 | (Feb 4, 2026)